J.P. Morgan: RemeGen posts recurring profits for two consecutive quarters; cuts 2027 revenue forecast
Product sales rose 33% year on year in the third quarter of 2026, driving RemeGen to a second consecutive quarter of recurring profitability. J.P. Morgan is positive on the full-year product sales and break-even targets but has lowered its 2027 revenue forecast and its A- and H-share price targets.